rss
Ann Rheum Dis 2003;62:501-509 doi:10.1136/ard.62.6.501
  • Review

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs

  1. J Martel-Pelletier,
  2. D Lajeunesse,
  3. P Reboul,
  4. J-P Pelletier
  1. Osteoarthritis Research Unit, Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada
  1. Correspondence to:
    Professor J Martel-Pelletier, Osteoarthritis Research Unit, CHUM, Hôpital Notre-Dame, 1560 rue Sherbrooke Est, Pavillon deSève, Montréal (Québec) H2L 4M1, Canada;
    jm{at}martelpelletier.ca
  • Accepted 22 November 2002

Abstract

Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.